Acurx Pharmaceuticals Inc. Common Stock (ACXP)

About ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parentera…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

4

Website

www.acurxpharma.com/

Fundamentals

1-day range

$1.37$1.49

Market cap

$6.27M

P/E (trailing)

—

P/E (forward)

-0.79

EPS (trailing)

$-4.46

Dividend yield

—

Beta

-2.09

Avg. volume

121.5K

Forecasts

3 analyst ratings

Acurx Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ACXP

  Acurx Pharmaceuticals Inc. Common Stock

  $1.45

  ▼ 1.03%
  Market cap $6.27MP/E —
  $1.31$8.34
• HCWB

  HCW Biologics Inc. Common Stock

  $3.39

  ▲ 6.94%
  Market cap $6.19MP/E —
  $1.5$39.96
• APVO

  Aptevo Therapeutics Inc. Common Stock

  $2.36

  ▼ 2.48%
  Market cap $6.18MP/E 0.00
  $2.3$48.78
• PULM

  Pulmatrix Inc. Common Stock

  $1.51

  ▼ 0.66%
  Market cap $6.06MP/E —
  $1.16$5.5
• XBIO

  Xenetic Biosciences Inc. Common Stock

  $3.98

  ▲ 1.66%
  Market cap $6.53MP/E —
  $1.9$13.93
• ALZN

  Alzamend Neuro Inc. Common Stock

  $1.66

  ▼ 0.30%
  Market cap $6.61MP/E —
  $0.84$2.68
• IMNN

  Imunon Inc. Common Stock

  $1.58

  ▼ 1.25%
  Market cap $6.64MP/E —
  $1.47$6.35

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Let's have a look at the top gainers and losers in the middle of the day of today's session.
  ChartMill · 8/17/2026
• 12 Health Care Stocks Moving In Monday's Intraday Session
  Benzinga · 8/17/2026
• U.S. Patent And Trademark Office Allows Trademark Application For CIFBEZY.
  benzinga · 8/17/2026
• Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
  Yahoo · 8/17/2026
• FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat
  Benzinga · 8/17/2026
• Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/14/2026
• Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/14/2026
• Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
  Yahoo · 8/14/2026
• Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
  Benzinga · 8/14/2026

• Carl Sailer · April 20, 2026 · Grant

  2.1K
• James J. Donohue · April 20, 2026 · Grant

  2.1K
• Shawah Robert G. · April 20, 2026 · Grant

  25.9K
• Jack H. Dean · April 20, 2026 · Grant

  2.1K
• Joseph C. Scodari · April 20, 2026 · Grant

  2.1K
• David P. Luci · April 20, 2026 · Grant

  37.1K
• Thomas L. Harrison · April 20, 2026 · Grant

  2.1K
• Robert J. Deluccia · April 20, 2026 · Grant

  37.1K

Institutional Ownership

March 31, 2026

Total shares held

167.0K

Total value held

$545.1K

Institutional holders

21